nach oben

Digestive Diseases and Sciences

Erschienen in:

01.11.2008 | Original Paper

An Open-Labeled Study of Rebamipide Treatment in Chronic Gastritis Patients with Dyspeptic Symptoms Refractory to Proton Pump Inhibitors

verfasst von: Taned Chitapanarux, Ong-ard Praisontarangkul, Nirush Lertprasertsuke

Erschienen in: Digestive Diseases and Sciences | Ausgabe 11/2008

Einloggen, um Zugang zu erhalten

Abstract

To assess the efficacy of rebamipide therapy in chronic gastritis patients with refractory dyspeptic symptoms, we enrolled 30 patients with chronic gastritis nonresponsive to the antisecretory medications, proton pump inhibitors. Upper gastrointestinal endoscopy was performed in all patients to confirm and evaluate the severity of gastritis by gastric mucosal injury score and the histology by the updated Sydney system before and after treatment with rebamipide 300 mg daily for 8 weeks. At the end of the study, significant improvement in the scores for symptoms (epigastralgia, stomach heaviness, and abdominal fullness) and endoscopic mucosal injury were observed for all patients. The degrees of neutrophil activity in antrum and mononuclear cell inflammation in both body and antrum significantly decreased from baseline. Improvement of gastritis might be the mechanism by which rebamipide prevents gastric mucosal inflammation. In conclusion, rebamipide treatment improved symptom, endoscopic, and histologic features of chronic gastritis in patients with refractory dyspeptic symptoms.

Atisook K, Kachinthorn U, Luengrojanakul P, Tanwandee T, Pakdirat P, Puapairoj A (2003) Histology of gastritis and Helicobacter pylori infection in Thailand: a nationwide study of 3776 cases. Helicobacter 8:132–141. doi:10.1046/j.1523-5378.2003.00134.x PubMedCrossRef

Hojgaard L, Matzen P, Christofferson P (1987) Gastritis—a clinical entity? Scand J Gastroenterol Suppl 128:90–93. doi:10.3109/00365528709090974 PubMedCrossRef

Elta GH, Appelman HD, Behler EM, Wilson JA, Nostrant TJ (1987) A study of the correlation between endoscopic and histological diagnoses in gastroduodenitis. Am J Gastroenterol 82:749–753PubMed

Boyko DA, Flind AC, Guslandi M (1986) Non-ulcer dyspepsia. Lancet 328:113. doi:10.1016/S0140-6736(86)91651-X CrossRef

Chey WD, Wong BC (2007) Practice parameters committee of the American College of Gastroenterology: American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 102:1808–1825. doi:10.1111/j.1572-0241.2007.01393.x PubMedCrossRef

Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T (2004) Pharmacogenomics of proton pump inhibitors. Pharmacogenomics 5:181–202. doi:10.1517/phgs.5.2.181.27483 PubMedCrossRef

Correa P (1992) Human gastric carcinogenesis: a multistep and multifactorial process—First American Cancer Society Award Lecture on cancer epidemiology and prevention. Cancer Res 52:6735–6740PubMed

Naito Y, Yoshikawa T, Iinuma S, Yagi N, Matsuyama K, Boku Y, Fujii T, Yoshida N, Kondo M, Sasaki E (1998) Rebamipide protects against indomethacin-induced gastric mucosal injury in healthy volunteers in double-blind, placebo-controlled study. Dig Dis Sci 43:83S–89SPubMed

Nebiki H, Higuchi K, Arakawa T, Ando K, Uchida T, Ito H, Harihara S, Kuroki T, Kobayashi K (1998) Effect of rebamipide on Helicobacter pylori infection in patients with peptic ulcer. Dig Dis Sci 43:203S–206S. doi:10.1023/A:1018813229334 PubMedCrossRef

10.

Ishihara K, Komuro Y, Nishiyama N, Yamasaki K, Hotta K (1992) Effect of rebamipide on mucus secretion by endogenous prostaglandin-independent mechanism in rat gastric mucosa. Arzneimittelforschung 42:1462–1466PubMed

11.

Song DU, Ryu MH, Chay KO, Jung YD, Yang SY, Cha SH, Lee MW, Ahn BW (1998) Effect of rebamipide on glycosaminoglycan content of the ulcerated rat stomach. Fundam Clin Pharmacol 12:546–552PubMedCrossRef

12.

Yamasaki K, Kanbe T, Chijiwa T, Ishiyama H, Morita S (1987) Gastric mucosal protection by OPC-12759, a novel antiulcer compound, in the rat. Eur J Pharmacol 142:23–29. doi:10.1016/0014-2999(87)90649-2 PubMedCrossRef

13.

Kleine A, Kluge S, Peskar BM (1993) Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in rats. Dig Dis Sci 38:1441–1449. doi:10.1007/BF01308601 PubMedCrossRef

14.

Ogino K, Hobara T, Ishiyama H, Yamasaki K, Kobayashi H, Izumi Y, Oka S (1992) Antiulcer mechanism of action of rebamipide, a novel antiulcer compound, on diethyl-dithiocarbamate-induced antral gastric ulcers in rats. Eur J Pharmacol 212:9–13. doi:10.1016/0014-2999(92)90065-C PubMedCrossRef

15.

Suzuki M, Miura S, Mori M, Kai A, Suzuki H, Fukumura D, Suematsu M, Tsuchiya M (1994) Rebamipide, a novel anti-ulcer agent, attenuates Helicobacter pylori induced gastric mucosal cell injury associated with neutrophil derived oxidants. Gut 35:1375–1378. doi:10.1136/gut.35.10.1375 PubMedCrossRef

16.

Yoshikawa T, Naito Y, Tanigawa T, Kondo M (1993) Free radical scavenging activity of the novel anti-ulcer agent rebamipide studied by electron spin resonance. Arzneimittelforschung 43:363–366PubMed

17.

Naito Y, Yoshikawa T, Tanigawa T, Sakurai K, Yamasaki K, Uchida M, Kondo M (1995) Hydroxyl radical scavenging by rebamipide and related compounds: electron paramagnetic resonance study. Free Radic Biol Med 18:117–123. doi:10.1016/0891-5849(94)00110-6 PubMedCrossRef

18.

Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A (1998) Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci 43 [Suppl 9]:5S–13SPubMed

19.

Hiquchi K, Arakawa T, Nebiki H, Uchida T, Fujiwara Y, Ando K, Yamasaki K, Takaishi O, Fukuda T, Kobayashi K, Kuroki T (1998) Rebamipide prevents recurrence of gastric ulcers without affecting Helicobacter pylori status. Dig Dis Sci 43 [Suppl]:S99–S106

20.

Haruma K, Ito M, Kido S, Manabe N, Kitadai Y, Samii M, Tanaka S, Yoshihara M, Chayama K (2002) Long-term rebamipide therapy improves Helicobacter pylori-associated chronic gastritis. Dig Dis Sci 47:862–867. doi:10.1023/A:1014716822702 PubMedCrossRef

21.

Karvonen AL, Sipponen P, Lehtola J, Ruokonen A (1983) Gastric mucosal erosions. An endoscopic, histologic, and functional study. Scand J Gastroenterol 18:1051–1056PubMedCrossRef

22.

Miehlke S, Hackelsberger A, Meining A, Hatz R, Lehn N, Malfertheiner P, Stolte M, Bayerdörffer E (1988) Severe expression of corpus gastritis is characteristic in gastric cancer patients infected with Helicobacter pylori. Br J Cancer 78:263–266CrossRef

23.

Fiocca R, Villani L, Luinetti O, Gianatti A, Perego M, Alvisi C, Turpini F, Solcia E (1992) Helicobacter colonization and histopathological profile of chronic gastritis in patients with or without dyspepsia, mucosal erosion and peptic ulcer; a morphological approach to the study of ulcerogenesis in man. Virchows Arch A Pathol Anat Histopathol 420:489–498PubMedCrossRef

24.

Stolte M, Eidt S (1992) Chronic erosions of the antral mucosa: a sequela of Helicobacter pylori-induced gastritis. Z Gastroenterol 30:846–850. doi:10.1007/BF01600253

25.

Gallo N, Zambon CF, Navaglia F, Basso D, Guariso G, Grazia Piva M, Greco E, Mazza S, Fogar P, Rugge M, Di Mario F, Plebani M (2003) Helicobacter pylori infection in children and adults: a single pathogen but a different pathology. Helicobacter 8:21–28. doi:10.1046/j.1523-5378.2003.00120.x PubMedCrossRef

26.

Yamamura F, Yoshikawa N, Akita Y, Mitamura K, Miyasaka N (1999) Relationship between Helicobacter pylori infection and histologic features of gastritis in biopsy specimens in gastroduodenal diseases, including evaluation of diagnosis by polymerase chain reaction assay. J Gastroenterol 34:461–466. doi:10.1007/s005350050297 PubMedCrossRef

27.

Kamada T, Suqiu K, Hata J, Kusunoki H, Hamada H, Kido S, Naqashima Y, Kawamura Y, Tanaka S, Chayama K, Haruma K (2006) Evaluation of endoscopic and histological findings in Helicobacter pylori-positive Japanese young adult. J Gastroenterol Hepatol 21:258–261. doi:10.1111/j.1440–1746.2006.04128.x PubMedCrossRef

28.

Zhang C, Yamada N, Wu YL, Wen M, Matsuhisa T, Matsukura N (2005) Comparison of Helicobacter pylori infection and gastric mucosal histological features of gastric ulcer patients with chronic gastritis patients. World J Gastroenterol 11:976–981PubMed

29.

Talley NJ, Riff DS, Schwartz H, Marcuard SP (2001) Double-blind placebo-controlled multicenter studies of rebamipide, a gastroprotective drug, in the treatment of functional dyspepsia with or without Helicobacter pylori infection. Aliment Pharmacol Ther 15:1603–1611. doi:10.1046/j.1365-2036.2001.01074.x PubMedCrossRef

30.

Miwa H, Osada T, Nagahara A, Ohkusa T, Hojo M, Tomita T, Hori K, Matsumoto T, Sato N (2006) Effect of a gastro-protective agent, rebamipide, on symptom improvement in patients with functional dyspepsia: a double-blind placebo-controlled study in Japan. J Gastroenterol Hepatol 21:1826–1831. doi:10.1111/j.1440-1746.2006.04446.x PubMedCrossRef

31.

Terano A, Arakawa T, Sugiyama T, Suzuki H, Joh T, Yoshikawa T, Higuchi K, Haruma K, Murakami K, Kobayashi K (2007) Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following therapy for Helicobacter pylori in Japanese population: a randomized, double-blind, placebo-controlled trial. J Gastroenterol 42:690–693. doi:10.1007/s00535-007-2076-2 PubMedCrossRef

32.

Kim HK, Kim JI, Kim JK, Han JY, Park SH, Choi KY, Chung IS (2007) Preventive effect of rebamipide on NSAID-induced gastric mucosal injury and reduction of gastric mucosal blood flow in healthy volunteers. Dig Dis Sci 52:1776–1782. doi:10.1007/s10620-006-9367-y PubMedCrossRef

Titel: An Open-Labeled Study of Rebamipide Treatment in Chronic Gastritis Patients with Dyspeptic Symptoms Refractory to Proton Pump Inhibitors
verfasst von: Taned Chitapanarux
Ong-ard Praisontarangkul
Nirush Lertprasertsuke
Publikationsdatum: 01.11.2008
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 11/2008
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-008-0255-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2008

Correlation of Quantitative Assay of HBsAg and HBV DNA Levels During Chronic HBV Treatment

Deep Vein Thrombosis and Pulmonary Embolism in Cirrhosis Patients

Predictive Factors Associated with the Progression to Hepatic Failure Caused by Lamivudine-Resistant HBV

Z-LLY-FMK Can Attenuate Hepatocyte Apoptosis After Bile Duct Ligation in Rat

Promoting Informed Choice of Unsedated Colonoscopy: Patient-Centered Care for a Subgroup of U.S. Veterans